EIP And Diffusion Combine To Form CNS Firm With Dementia Focus
Neflamapimod At Heart Of All-Stock Merger
The US biotechs are joining forces to form a new, listed company with sufficient cash to advance EIP’s potentially disease-modifying drug candidate through Phase II development in dementia with Lewy bodies, which presents a high unmet need.
